Drugs Made In America Acquisition (DMAAR) Equity Ratio (2024 - 2025)
Drugs Made In America Acquisition (DMAAR) reported Equity Ratio of 0.03 for Q4 2025, up 93.19% on a YoY basis from 0.02 in Q4 2024, and up 1.82% quarter-over-quarter from 0.03 in Q3 2025.
Drugs Made In America Acquisition (DMAAR) Equity Ratio (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition has reported Equity Ratio for 2 years, with the latest figure at 0.03 in Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 93.19% year-over-year to 0.03; the trailing twelve-month figure through Dec 2025 stood at 0.03 (up 93.19% YoY), and the FY2025 full-year result was 0.03, up 93.19% from the prior year.
- Equity Ratio for Q4 2025 stood at 0.03, up from 0.03 in the prior quarter.
- The five-year high for Equity Ratio was 0.03 in Q4 2025, with the low at 0.44 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | -0.03 |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - | -0.04 |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - | -0.04 |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - | -0.05 |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - | -0.04 |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - | -0.04 |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - | -0.03 |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - | -0.04 |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - | -0.04 |
| 10 | Drugs Made In America Acquisition | - | - | - | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.03 |
| Sep 30, 2025 | -0.03 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.03 |
| Dec 31, 2024 | -0.44 |